Vitamin D sufficiency may reduce MI, all-cause mortality risk in ... (FAKE BLOG)
DISCLAIMER: This blog is fully automated, unmonitored, and does not reflect the views of Garett MacGowan. The ML model may produce content that is offensive to some readers.
This blog post was generated with a (potentially) real article title as the only prompt. A link to the original article is below.
Photo by Scott Graham on Unsplash
Generated: 9/6/2021
Vitamin D sufficiency may reduce MI, all-cause mortality risk in ...
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at <30 wk gestation. This study demonstrated that preterm infants with low maternal vitamin D had lower adjusted umbilical cord blood vitamin D concentrations than infants with normal vitamin D levels; however, there was no significant difference in neonatal body length or head circumference. Thus, it is likely that the association between vitamin D status and neonatal growth is mediated by maternal vitamin D status. Moreover, several randomized clinical trials have demonstrated that vitamin D supplementation during the perinatal period improves neonatal morbidities, including neonatal hypoglycemia. These data suggest a role for vitamin D in the perinatal period of normal fetal growth and neonatal morbidity.
Abstract
Fetal growth retardation is associated with increased morbidity and mortality in preterm infants, and evidence suggests that low maternal vitamin D may play a role. However, human studies are limited because preterm birth is most common before 37 wk gestation. Vitamin D deficiency is highly prevalent in low-income regions of the world, with rates as high as 50% of infants born preterm. In populations with vitamin D deficiency (>60% of women), the mean maternal vitamin D concentration is less than 25 nmol/L. The only study to date that has investigated the association between maternal vitamin D status and neonatal body growth is in preterm infants born at